Experimental Treatment Sebetralstat Shows Promise in Phase 3 HAE Study
source: shutterstock.com

Experimental Treatment Sebetralstat Shows Promise in Phase 3 HAE Study

Imagine if you had recurring attacks of severe and unexplained swelling beneath your skin. For individuals living with hereditary angioedema (HAE), a rare inherited disorder, this isn't just a mere…

Continue Reading Experimental Treatment Sebetralstat Shows Promise in Phase 3 HAE Study
Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study
https://unsplash.com/photos/Y14ONzYtxb4

Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study

  Last year, the FDA placed a clinical hold on an Investigational New Drug (IND) application for deucrictibant for the on-demand and prophylactic treatment of individuals living with hereditary angioedema…

Continue Reading Deucrictibant Reduces Monthly HAE Attacks by 84.5% in Phase 2 Study
Positive Phase 1 Data Available on Sebetralstat for HAE
Photo courtesy of Towfiqu Barbhuiya on Unsplash

Positive Phase 1 Data Available on Sebetralstat for HAE

  According to a late October 2022 news release from pharmaceutical company KalVista Pharmaceuticals, Inc. (“KalVista”), the company released positive data from a Phase 1 study evaluating oral sebetralstat for…

Continue Reading Positive Phase 1 Data Available on Sebetralstat for HAE
Company Halts Development of Hereditary Angioedema Drug Following Safety Issues
source: shutterstock.com

Company Halts Development of Hereditary Angioedema Drug Following Safety Issues

According to a story from BioPharma Dive, KalVista Pharmaceuticals has halted its clinical trial evaluating an investigational therapy in development for hereditary angioedema. The trial had included a total of…

Continue Reading Company Halts Development of Hereditary Angioedema Drug Following Safety Issues
Donidalorsen Reduces HAE Attacks, Study Shows
Hand swollen during hereditary angioedema attack. Sourced from Wikimedia Commons

Donidalorsen Reduces HAE Attacks, Study Shows

In patients with hereditary angioedema (HAE), the C1-inhibitor blood protein does not function properly, allowing bradykinin peptides to build up in the body. These then cause inflammation and fluid leakage;…

Continue Reading Donidalorsen Reduces HAE Attacks, Study Shows
ERN-RITA Enables Virtual Health Consultations With European Experts
source: pixabay.com

ERN-RITA Enables Virtual Health Consultations With European Experts

Note: this story was originally published by HAE Junior, a Patient Worthy partner Interview with Malena Vetterli from the European Reference Network (ERN-RITA) for rare immunodeficiencies, autoinflammatory and autoimmune diseases.…

Continue Reading ERN-RITA Enables Virtual Health Consultations With European Experts

HAE Junior’s Drawing Exhibition Unveiled the Dreams and Ambitions of Children Living With Hereditary Angioedema

HAE Junior’s drawing exhibition unveiled the dreams, wishes, and ambitions of children & teenagers living with hereditary angioedema (HAE). The patient organization HAE Junior organized a drawing exhibition named We…

Continue Reading HAE Junior’s Drawing Exhibition Unveiled the Dreams and Ambitions of Children Living With Hereditary Angioedema
Experimental Hereditary Angioedema Treatment Performs Well in Phase 2 Trial
source: pixabay.com

Experimental Hereditary Angioedema Treatment Performs Well in Phase 2 Trial

According to a story from PR Newswire, the biotechnology company Ionis Pharmaceuticals recently announced promising findings from its phase 2 clinical trial. This clinical trial was evaluating the company's experimental…

Continue Reading Experimental Hereditary Angioedema Treatment Performs Well in Phase 2 Trial